Workflow
日化美妆
icon
Search documents
片仔癀又做LP
FOFWEEKLY· 2025-10-17 04:01
近日, 漳州片仔癀药业股份有限公司发布关于投资参与中金医疗基金暨关联交易的公告,拟参设 中金(漳州)医疗产业投资合伙企业(有限合伙) (暂定名,以市场监督管理部门核准为准;以下简称"中金医疗基金")。 每日|荐读 论坛: 2025母基金年度论坛圆满举办:内地携手香港,共话科创时代中国力量 荐读: 重新发现香港:科创时代的新蓝图 榜单: 「2025投资机构软实力排行榜」正式发布 热文: 今天,LP、GP都往厦门飞 据悉,本次中金医疗基金目标募集规模为10亿元, 漳州片仔癀药业股份有限公司(以下简称"公司")全资子公司漳州片仔癀投资管理有限公司(以 下简称"片仔癀投资")拟作为有限合伙人以自有或自筹资金认缴出资人民币20,000 万元,占中金医疗基金目标募集规模的比例为20%。 来源: 漳州片仔癀药业股份有限公司 公告指出: 基金的主要投资领域为医疗大健康投资方向,主要投资于中医药、生物医药、医疗器械、医疗服务、日化美妆和康养大健康等相关产 业,包括但不限于片仔癀产业链项目、片仔癀产业园以及招商引资落地漳州的项目。 ...
中金漳州医疗产业投资合伙企业成立,片仔癀拟出资2亿元占其募资比例为20%
Cai Jing Wang· 2025-10-15 08:14
近日,天眼查工商信息显示,中金(漳州)医疗产业投资合伙企业(有限合伙)成立,执行事务合伙人 为中金资本运营有限公司,出资额为10亿人民币,经营范围为以自有资金从事投资活动。合伙人信息显 示,该企业由漳州高鑫发展有限公司、漳州片仔癀资产经营有限公司、漳州市产业股权投资有限公司、 中金资本运营有限公司等共同出资。 (天眼查、片仔癀公告) 片仔癀公告中提到,这一基金的主要投资领域为医疗大健康投资方向,主要投资于中医药、生物医药、 医疗器械、医疗服务、日化美妆和康养大健康等相关产业,包括但不限于片仔癀产业链项目、片仔癀产 业园以及招商引资落地漳州的项目。 其中,片仔癀全资子公司漳州片仔癀投资管理有限公司拟作为有限合伙人以自有或自筹资金认缴出资2 亿元,占中金医疗基金目标募集规模的比例为20%。 此前片仔癀曾发布相关公告,宣布旗下全资子公司漳州片仔癀投资管理有限公司拟作为有限合伙人投资 中金(漳州)医疗产业投资合伙企业(有限合伙),即中金医疗基金。 ...
中俄贸易额突破9000亿,国内市场有哪些俄罗斯品牌?你知道多少?
Sou Hu Cai Jing· 2025-10-08 20:12
通过市场调研和消费者访谈,我发现当前在中国市场比较活跃的俄罗斯品牌主要集中在以下几个领域: 食品饮料类俄罗斯品牌是进入中国市场最早、认知度最高的品类。根据中俄商会发布的《2025年中俄食 品贸易报告》,目前有超过200个俄罗斯食品饮料品牌进入中国市场,年销售额超过85亿元人民币。 其中,俄罗斯巧克力品牌在中国消费者中享有较高知名度。红十月(Krasny Oktyabr)是俄罗斯历史最悠 久的糖果制造商之一,创立于1851年,其"爱莲巧"巧克力和"松露"糖果在中国市场广受欢迎。据统计, 2025年上半年,红十月品牌在中国市场的销售额同比增长32%,线上销售渠道的增长率更是高达47%。 我朋友小李是俄罗斯文学爱好者,他告诉我:"红十月巧克力的包装设计很有特色,经常采用俄罗斯童 话和民间故事的元素,每次吃都有种文化体验感。"这种文化附加值成为俄罗斯食品在中国市场的独特 卖点。 上个月去商场闲逛,在超市的进口食品区,我发现了一个专门的俄罗斯食品专区。货架上摆满了各种包 装精美的巧克力、饼干、蜂蜜和伏特加。好奇心驱使我买了几样回家尝鲜。朋友们聚会时,我拿出这些 俄罗斯零食,没想到引起了大家的热烈讨论。"这个阿列卡巧克力 ...
片仔癀(600436.SH)拟斥2亿元参投中金医疗基金 布局医疗大健康领域
智通财经网· 2025-09-28 08:57
智通财经APP讯,片仔癀(600436.SH)公告,公司拟参与投资中金(漳州)医疗产业投资合伙企业(有限合 伙)(暂定名,简称"中金医疗基金")。公司全资子公司漳州片仔癀投资管理有限公司(简称"片仔癀投资") 拟作为有限合伙人以自有或自筹资金认缴出资2亿元,占中金医疗基金目标募集规模的比例为20%。 据悉,本基金的主要投资领域为医疗大健康投资方向,主要投资于中医药、生物医药、医疗器械、医疗 服务、日化美妆和康养大健康等相关产业,包括但不限于片仔癀产业链项目、片仔癀产业园以及招商引 资落地漳州的项目。 ...
片仔癀拟斥2亿元参投中金医疗基金 布局医疗大健康领域
智通财经网· 2025-09-28 08:57
智通财经APP讯,片仔癀(600436.SH)公告,公司拟参与投资中金(漳州)医疗产业投资合伙企业(有限合 伙)(暂定名,简称"中金医疗基金")。公司全资子公司漳州片仔癀投资管理有限公司(简称"片仔癀投资") 拟作为有限合伙人以自有或自筹资金认缴出资2亿元,占中金医疗基金目标募集规模的比例为20%。 据悉,本基金的主要投资领域为医疗大健康投资方向,主要投资于中医药、生物医药、医疗器械、医疗 服务、日化美妆和康养大健康等相关产业,包括但不限于片仔癀产业链项目、片仔癀产业园以及招商引 资落地漳州的项目。 ...
中恒集团2025年上半年实现业绩双增 强化主业拓展与多元协同
Group 1 - The core viewpoint of the articles highlights that Zhongheng Group has achieved revenue growth and profit increase in the first half of 2025, driven by market expansion, R&D innovation, and diversified layout [1][2] - In the first half of 2025, Zhongheng Group reported a revenue of 1.451 billion yuan, a year-on-year increase of 2.84%, and a net profit attributable to shareholders of 27.08 million yuan, up 23.59% [1] - The pharmaceutical manufacturing segment generated an external revenue of 1.044 billion yuan, reinforcing the company's revenue base [1] Group 2 - Zhongheng Group is focusing on innovation and product layout to establish a new growth curve, optimizing its R&D system and signing cooperation agreements with key laboratories [2] - The company has received clinical trial approval for its innovative drug project "Sanqi Granules" and has introduced a candidate drug molecule for chronic heart failure, expanding market opportunities in chronic kidney disease and cardiovascular fields [2] - The health consumption segment has launched 26 new products, contributing to steady revenue and profit growth [2] Group 3 - Zhongheng Group repurchased 118 million shares for 301 million yuan, accounting for 3.56% of the total share capital, reflecting management's confidence in future development [3] - The company's subsidiary, Laimei Pharmaceutical, has developed "Injectable Esomeprazole Sodium," recognized as a major technological innovation product in Chongqing for 2024, addressing key technical challenges in synthesis and freeze-drying stability [3] - This innovation not only breaks the import monopoly but also provides better medication options for patients, showcasing the company's strength in formulation R&D and production process innovation [3]
扬“链”上之帆,奏共赢乐章——第三届中国国际供应链促进博览会如约启幕
Xin Hua Wang· 2025-07-16 16:43
Core Insights - The third China International Supply Chain Promotion Expo has commenced with the theme "Linking the World, Creating the Future," emphasizing global cooperation and innovation in supply chains [1][5][6] Group 1: Event Overview - The expo is the world's first national-level exhibition focused on supply chains, showcasing a significant increase in international participation, with 651 companies from 75 countries and regions, and foreign exhibitors rising from 32% to 35% [2][5] - Notable returning participants include Apple and Cargill, while over 230 new companies are participating for the first time, highlighting the event's growing appeal [2][3] Group 2: Innovation and Technology - The expo features new products and technologies, with a focus on artificial intelligence and green technologies, as demonstrated by Nvidia's showcase of AI-driven solutions [3][4] - The event is expected to unveil over 100 new products, marking a 10% increase from the previous year, indicating a strong emphasis on innovation [4] Group 3: Global Collaboration - The "Beijing Initiative" released at the opening calls for enhanced collaboration among global businesses to leverage innovation and resource integration, positioning the expo as a key platform for building a resilient and efficient supply chain ecosystem [5][6] - Companies like Panasonic and Schneider Electric are leveraging the expo to deepen their integration with Chinese supply chains and promote sustainable practices [5]